• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Neuropathol Commun . In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Acta Neuropathol Commun


. 2022 Sep 5;10(1):124.
doi: 10.1186/s40478-022-01426-4.
In vitro and in vivo differences in neurovirulence between D614G, Delta And Omicron BA.1 SARS-CoV-2 variants


Lisa Bauer[SUP] #[/SUP][SUP] 1 [/SUP], Melanie Rissmann[SUP] #[/SUP][SUP] 1 [/SUP], Feline F W Benavides[SUP] 1 [/SUP], Lonneke Leijten[SUP] 1 [/SUP], Peter van Run[SUP] 1 [/SUP], Lineke Begeman[SUP] 1 [/SUP], Edwin J B Veldhuis Kroeze[SUP] 1 [/SUP], Bas Lendemeijer[SUP] 2 [/SUP], Hilde Smeenk[SUP] 2 [/SUP], Femke M S de Vrij[SUP] 2 [/SUP], Steven A Kushner[SUP] 2 [/SUP], Marion P G Koopmans[SUP] 1 [/SUP], Barry Rockx[SUP] 1 [/SUP], Debby van Riel[SUP] 3 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with various neurological complications. Although the mechanism is not fully understood, several studies have shown that neuroinflammation occurs in the acute and post-acute phase. As these studies have predominantly been performed with isolates from 2020, it is unknown if there are differences among SARS-CoV-2 variants in their ability to cause neuroinflammation. Here, we compared the neuroinvasiveness, neurotropism and neurovirulence of the SARS-CoV-2 ancestral strain D614G, the Delta (B.1.617.2) and Omicron BA.1 (B.1.1.529) variants using in vitro and in vivo models. The Omicron BA.1 variant showed reduced neurotropism and neurovirulence compared to Delta and D614G in human induced pluripotent stem cell (hiPSC)-derived cortical neurons co-cultured with astrocytes. Similar differences were obtained in Syrian hamsters inoculated with D614G, Delta and the Omicron BA.1 variant 5 days post infection. Replication in the olfactory mucosa was observed in all hamsters, but most prominently in D614G inoculated hamsters. Furthermore, neuroinvasion into the CNS via the olfactory nerve was observed in D614G, but not Delta or Omicron BA.1 inoculated hamsters. Furthermore, neuroinvasion was associated with neuroinflammation in the olfactory bulb of hamsters inoculated with D614G. Altogether, our findings suggest differences in the neuroinvasive, neurotropic and neurovirulent potential between SARS-CoV-2 variants using in vitro hiPSC-derived neural cultures and in vivo in hamsters during the acute phase of the infection.

Keywords: Brain olfactory bulb; COVID-19; Coronavirus; Interferon; Microglia activation; Neuroinvasion; Neurotropism; Neurovirulence; SARS-CoV-2.
 
Back
Top Bottom